Company Overview and News
KUALA LUMPUR (Oct 8): Construction counters this morning reacted negatively to news of the government's decision to retender MRT2's underground work, after terminating MMC-Gamuda KVMRT Sdn Bhd as the contractor.
5226 5253 5263 7078
KUALA LUMPUR: Econpile Holdings Bhd , Destini Bhd , Sentoria Group Bhd and Dayang Enterprise Holdings Bhd are among the stocks to watch today, according to JF Apex Research.
4634 GMALY BSTHY 4715 GMALF 5253 5141 5213 2771 GEBHF
KUALA LUMPUR (Aug 29): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 30) may include Econpile Holdings Bhd, Destini Bhd, Sentoria Group Bhd, Dayang Enterprise Holdings Bhd, Telekom Malaysia Bhd, Bumi Armada Bhd, CIMB Group Holdings Bhd, Taliworks Corp Bhd, YTL Corp Bhd, Pos Malaysia Bhd, Genting Malaysia Bhd, UMW Holdings Bhd, PPB Group Bhd, Boustead Holdings Bhd and 7-Eleven Malaysia Holdings Bhd.
BSTHY WLMIF BRDBF GMALF 4065 5253 5141 6742 5213 2771 CIMDF 5210 4634 GMALY WLMIY 1023 4588 4863 4715 YTLPF MYTEF BSMAF F34 1818
KUALA LUMPUR (Aug 29): Piling and foundation specialist Econpile Holdings Bhd has bagged a RM34.1 million contract from YTL Corp Bhd’s subsidiary Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd to undertake bored piling and pile cap works for a portion of the Gemas-Johor Baru electrified double track rail project.
5253 BSMAF 1818
KUALA LUMPUR (Aug 16): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Econpile Holdings Bhd, Apex Healthcare Bhd, Carlsberg Brewery Malaysia Bhd, Daibochi Bhd, Dialog Group Bhd, Hock Seng Lee Bhd, KPJ Healthcare Bhd, Sarawak Plantation Bhd, Sunway Construction Group Bhd and Warisan TC Holdings Bhd. Econpile Holdings Bhd secured a contract worth RM30.
APEXF KPJHF 5016 7090 6238 5878 5253 5263 2836 5135 7277
Pang: Raw materials make up 30% to 40% of total cost, so every 10% drop in raw material cost, it will result in a 2% to 3% growth in our gross margin. Photo by Shahrin Yahya
KUALA LUMPUR (July 9): Based on corporate announcements and news flow today, stocks that will draw some attention on Tuesday (July 10) may include: Atlan Holdings, Rohas Tecnic, N2N Connect, Adventa, Top Glove, Versatile Creative, LPI Capital and Econpile.
TGLVY 4995 APARINDS 0108 8621 7113 5253 TPGVF 5SO BSMAF 532259 1818
KUALA LUMPUR (July 9): Piling and foundation specialist Econpile Holdings Bhd has bagged a RM122 million contract to undertake working bored piles for the proposed Pavilion Damansara Heights (Parcel 2) mixed development at Jalan Damanlela here.
5253 BSMAF 1818
KUALA LUMPUR: The Malaysian stock market has seen foreign net selling almost on a daily basis since the 14th general election that led to a change of government for the first time in Malaysia’s history, but Rakuten Trade Sdn Bhd is expecting a potential return of foreign funds by the fourth quarter of 2018 (4Q18).
1155 KLKBY 2445 4863 MLYBY MLYNF 5253 MYTEF 0151 GEBHF
KUALA LUMPUR: The outlook for the second half of the year remains positive with foreign funds expected to return in the fourth quarter, according to Rakuten Trade head of research Kenny Yee.
1155 KLKBY 2445 4863 MLYBY MLYNF 5253 MYTEF 0151 BSMAF GEBHF 1818
KUALA LUMPUR (July 5): Rakuten Trade Sdn Bhd, a joint venture between Kenanga Investment Bank Bhd and Japan's Rakuten Securities Inc, remains positive on Malaysian stocks despite the heavy selldown seen in the last two months.
KUALA LUMPUR (June 13): The FBM KLCI pared some of its loss at the midday break today and was down 0.25%, dragged by select blue chips.
PBLOF 7113 5253 BATS TPGVF 4162 AMMHF 1295 7153 2089 7077 5226 1201 PNAGF SPMXF UPBMF 7087 6033 TGLVY PNADF 4588 1015 SPMXY 5819 BSMAF 3719 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...